- Home
- ALTO vs AVIR Comparison
ALTO vs AVIR Comparison
Compare ALTO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALTO | AVIR |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.7M | 399.3M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALTO | AVIR |
|---|---|---|
| Price | $5.18 | $4.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 2.6M | 365.4K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.51 | 3.00 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $917,927,000.00 | $351,367,000.00 |
| Revenue This Year | $6.66 | N/A |
| Revenue Next Year | $0.43 | N/A |
| P/E Ratio | $103.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $2.78 |
| 52 Week High | $6.11 | $6.45 |
Technical Indicators
Market Signals| Indicator | ALTO | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 50.28 |
| Support Level | $4.27 | $4.14 |
| Resistance Level | $6.02 | $5.04 |
| Average True Range (ATR) | 0.39 | 0.23 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 19.83 | 51.80 |
Price Performance
Historical ComparisonAbout ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.